Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200834 | 1.00 | TLR7 (0.53) | TLR7 | |
| SCHEMBL6031026 | 0.85 | TLR7 (0.57) | TLR7 | |
| SCHEMBL4792794 | 0.84 | TLR7 (0.37) | TLR7 | |
| SCHEMBL4336407 | 0.83 | TLR7 (0.55) | TLR7 | |
| SCHEMBL4331154 | 0.83 | TLR7 (0.56) | TLR7 | |
| SCHEMBL676401 | 0.82 | TLR7 (0.60) | TLR7 | |
| SCHEMBL29852303 | 0.82 | TLR7 (0.60) | TLR7 | |
| SCHEMBL31006041 | 0.82 | TLR8 (0.55) | TLR7 | |
| SCHEMBL17783025 | 0.81 | TLR7 (0.51) | TLR7 | |
| SCHEMBL5736958 | 0.81 | TLR7 (0.56) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023097237-A2 | CYTOSOLIC BACTERIAL PATHOGENS ATTENUATED FOR SPREAD FROM TUMORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | claimed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | claimed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | claimed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-12201684-B2 | Compositions for stimulation of mammalian innate immune resistance to pathogens | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240417738-A1 | IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER | OHIO STATE INNOVATION FOUNDATION | 2024-12-19 | — | — | US | disclosed |
| EP-3484518-B1 | ANTIBODY ADJUVANT CONJUGATES | UNIV LELAND STANFORD JUNIOR (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-110234401-B | Methods and compositions for adaptive immunomodulation | 德克萨斯大学系统董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-20240033348-A1 | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | Pulmotect, Inc. | 2024-02-01 | — | — | US | disclosed |
| US-11826422-B2 | Methods and compositions for adaptive immune modulation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4218824-A2 | IMMUNOCONJUGATE SYNTHESIS METHOD | Bolt Biotherapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20120082700-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2012-04-05 | — | — | US | disclosed |
| US-7560436-B2 | Methods of treating gastrointestinal inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| US-7115622-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-30 | — | — | US | disclosed |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-08 | — | — | US | disclosed |
| US-6664265-B2 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-16 | — | — | US | disclosed |
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187016-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885 |
| US-20050143413-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885 |
| US-20040067975-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885 |
| US-20070004654-A1 | Methods of treating gastrointestinal inflammation | IFNG, IFNAR1, TNF | TLR7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.